EU panel backs approval of Pfizer's leukemia drug Bosulif

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended that Pfizer's Bosulif, or bosutinib, be approved to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia who didn't respond to or can't tolerate other treatments. The drug, a tyrosine kinase inhibitor, was cleared by the FDA in September.

View Full Article in:

Pharmaceutical Business Review Online · Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT